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Biomarkers of non-small cell lung cancer (NSCLC)
Lung cancer is the second most common cancer and the 
leading cause of cancer death for both men and women 
besides the important therapeutic achievements, the 
global disease control rate is still low. Other factors that 
can contribute to this unsuccessful scenario is the delay in 
the early detection, including also the absence of reliable 
biomarkers (1) and new drugs to fulfill an unmet medical 
need, specifically in NSCLC. 
Biomarkers play a crucial role in medicine, as indicators 
of normal or pathological processes or as tools to assess 
pharmacological responses to therapeutic interventions 
or as a prognostic and predictive aid to elucidate the risk 
of recurrence and progression and the possibilities of 
treatments effectiveness (2). For this reason, biomarkers 
have become one of the most studies aspects in cancer (3). 
The introduction of molecular biology in oncology, 
and mainly in NSCLC, made possible to identify 
drugable targets, for example EGFR mutation and ALK 
translocations among others. In this personalize treatment 
era, tissue became one of the most important treasure in 
the diagnosis and recurrence of the disease. Unfortunately, 
the amount of material is a big issue in lung cancer, due 
to the impossibility to reach the tumor. At this point, new 
tools have to be discovered in order to reveal the molecular 
information of the tumor. In this regards liquid biopsy has 
become a more and more important instrument in cancer 
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research and in the clinic. 
Liquid biopsy
Nowadays important efforts in molecular profiling of 
the tumors are allowing to develop new technology that 
permits to analyze the tumor characteristics in peripheral 
blood. Accordingly, the liquid biopsy refers to the analysis 
of components that can be isolated and analyzed from a 
blood sample as, circulating tumor cells (CTCs), cell free 
circulating DNA (circulating tumor DNA, ctDNA) and 
exosomes (a part of the secreted micro-vesicles) (4-6). In this 
regard, CTCs have been demonstrated to be good predictors 
for risk of metastatic progression, to monitor the response 
of an undergoing treatment, or to identify new targets and 
resistance mechanisms (7). On the other hand, ctDNA the 
most used component of the liquid biopsies is now being 
studied as possible biomarker and prognostic factor in 
cancer, although it is still difficult to standardize (8-11).
Nevertheless, the ultimate techniques developed in the 
field of sequencing and DNA amplification such as next 
generation sequencing (NGS) and digital droplet PCR 
(ddPCR) are transforming the molecular profiling of the 
tumor in a fast, easy, reliable and affordable manner (12-15).
Exosomes
Exosomes are the last frontier in liquid biopsies. Exosomes 
are spherical nano-size vesicles with a diameter between 
30 to 100 nm and with a well delimited round morphology 
by electron microscopy that are released by exocytosis 
from multivesicular bodies of late endosome (16). They 
are exocytosed in a constitutive manner by any cell in both 
physiological and pathological condition and can be found 
in several body fluids like urine, saliva, amniotic liquid or 
blood (17,18). Exosome’s composition may reflect that of 
the parental cells, so the study of cancer derived exosomes 
(DEX) are an important non-invasive surrogate of the 
tumor. Additionally, as exosomes are linked to cell-secretion 
pathway, they carry some common proteins independent 
of the cells of origin that allow the development of robust 
exosomes-isolation techniques. These proteins are well 
known exosomes markers, such as ALIX, CD9, CD63, 
CD81, HSP70 and TSG-101, among others (19).
Several methods are used to extract exosomes with 
no clear winner. The principal methods to isolate the 
exosomes are ultracentrifugation, sucrose density-gradient 
ultracentrifugation, exosome immunoprecipitation and the 
isolation using commercial kits (20).
Inside the exosomes
Exosomes contain a wide variety of components such as 
single-stranded RNA, long non-coding RNA (lncRNA), 
microRNA (miRNA), proteins and lipids. Recently also 
double-stranded DNA has also been found inside the 
exosomes giving a new chance for exosomes to become the 
principal diagnostic tool (21) (Figure 1). 
Since their discovery, the amount of information about 
his microvesicles has raised considerably, and a ‘microvesicle 
content database’ has been created to facilitate the access 
to all the newly discovered components (http://www.
microvesicles.org). Currently (June 2016) this database 
contained 92,897 proteins, 27,642 mRNA, 4,936 miRNAs 
and 584 lipids based on a total of 538 studies. Although 
many of these proteins are common to all cell types, 
some others are privative for a certain cell alteration or 
tumorogenic process and can be useful for the identification 
of the origin of these vesicles and thus can be an adequate 
biomarker to get more information from the tumor of origin. 
In addition the study of the lipids is interesting due to their 
role in the internalization process of exosomes and to the 
bioactive function of some of them such as prostaglandins 
and leukotrienes (22).
Additionally, Valadi et al. described for the first time 
the presence of miRNAs inside (23) exosomes. miRNAs 
are short single-stranded and non-coding RNA molecules 
that act regulating gene expression as oncogenic or tumor 
suppressor function. They are involved in progression, 
cellular differentiation, apoptosis or cell signaling.
Exosomes biology
Although exosomes can be released directly from the 
plasma membrane (24), most of them are derived from 
the endosomal compartment as a part of the endocytic 
machinery (25). A very important part of the exosomes 
formation is controlled for the mechanism of endosomal 
sorting complex required for transport (ESCRT), which 
is the responsible for the accumulation and sorting of 
molecules in the endocytic machinery. In tumor cells, where 
ESCRT is significantly altered, the protein profile inside 
the exosomes and the amount of exosomes released can 
be modified (26,27). Once exosomes are released from the 
cells other cells can capture these vesicles as a physiological 
response to the endocytic machinery fusing them either with 
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the plasma membrane or with lysosomes. If the exosomes 
fuse with lysosomes, their content will be degraded by 
proteolytic enzymes (28), but in contrast if the exosomes 
fuse with the plasma membrane, their content is released 
into the cytoplasm of the cell (29) being able to modify in a 
autocrine or paracrine manner the target cell behavior. This 
exosome’s uptake has reveal that they have a very important 
role in cell to cell communication or crosstalk (30,31) and 
three principal mechanisms governing this process have 
been described up to date (32). The first one, common to 
all type of vesicles is endocytosis, including pinocytosis, 
clathrin-mediated endocytosis, phagocytosis and others 
(30,33-35). A second mechanism is by direct binding of both 
cell and exosome membranes (36), leading to membranes 
fusion. Exosomes contain an enormous amount of surface 
proteins such as leptins, immunoglobulins, integrins and 
tetraspanins that are involved in their function, motility and 
internalization into the cells (34,37). The third mechanism is 
linked to ligand-receptor interaction that is the effect of the 
interplay of specific proteins in the exosome and the target 
cell surface (32). In this regard, tumor metastasis is not 
produced to random organs but to determine organs in each 
case and exosomes contribute to prepare the pre-metastatic 
niche. For example, integrin profiling in exosomes could be 
a feasible tool to identify possible organotropic metastasis 
before they have been produced (38).
Exosomes and cancer
In recent years, more and more studies are ongoing with 
regard to the function of exosomes and their application 
for tumor detection and treatment and several reports 
have demonstrated that exosomes can play pleiotropic 
roles affecting pivotal aspects of tumor development and 
growth (Figure 2). For instance, exosomes derived from 
prostate tumor cells act in a paracrine fashion inducing a 
reprogramming of cell metabolism and enhancing of cell 
proliferation (39). The fusion gene TMPRSS2:ERG and 
EGFR, both related with advanced prostate have been 
described inside the exosomes (40,41). Cells from renal 
carcinoma are able to release exosomes containing some 
miRNAs and other RNAs that transform normal endothelial 
cells into an activated angiogenic phenotype, and directing 
towards lung cancer metastasis (42). In other studies it has 
been demonstrated that exosomes derived from highly 
metastatic melanoma cells promote the pre-metastatic 
niche formation through the education of the bone marrow 
and by reprogramming its progenitor cells to a pro-
vasculogenic phenotype (43). On the other hand, another 
described role of exosomes in breast cancer and multiple 
myeloma is the ability to promote drug resistance through 
horizontal transfer (44,45). Exosomes are also involved 
in the creation of a pro-inflammatory microenvironment 
that promotes tumor growth by means of immunological 
proteins such as MHC-II, CD40 and CD40L. In breast 
cancer exosomes containing 27-Hydroxycholesterol (27-
OHC), a lipid associated with proliferation and metastasis 
in estrogen receptor positive (ER+) tumor cells, open a new 
window to understand how exosomes genesis is achieved 
and its correlation with the content of the cells of origin (46). 
Other studies performed in exosomes derived from ovarian 
cancer cell lines show that exosomes can carry functional 
Figure 1 Exosomes cargo. (A) Schematic picture of the content of an exosome; (B) diagram the principal proteins of the exosomes. 
A B
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proteins that reprogram cell metabolism of the cell 
enhancing the pentose phosphate pathway that is crucial for 
resisting oxidant injury and favors tumor survival (47-49). 
Many miRNAs profiles have been identified in cancer-
related exosomes. The oncogenic miRNA-21, upregulated 
in exosomes released by chronic myelogenous leukemia 
after Curcumin treatment, has been one of the most studied 
miRNA (50). Moreover, miRNA-21 has been found to be 
upregulated in different types of tumors such as esophageal 
squamous cell carcinoma (51) or glioblastoma (52), and its 
levels correlated with tumor progression and aggressiveness. 
miR-21 has also been described to be elevated in pancreatic 
carcinoma but no correlation was found with the stage of 
the disease (53). In ovarian cancer a profile of eight miRNAs 
(miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-
203, miR-205 and miR-214) in both tumor cells and tumor 
exosomes has been already analyzed in a large cohort of 467 
patients. The results revealed that levels of the miRNAs 
were different from those measured in benign disease, and 
the same miRNAs were undetectable in healthy donors (54).
Exosomes in NSCLC
As it was mentioned before, exosomes contain overexpressed 
or mutated proteins in the same proportion as the primary 
tumors. Therefore, in the specific case of exosomes obtained 
from NSCLC patients, EGFR (55), K-ras, claudins and other 
proteins can be analyzed. Recently, the translocation ALK-
EML4 has also been identifying inside the exosomes (56). 
Al-Nedawi et al. demonstrated that exosomes carrying 
EGFR were able to interact with endothelial cells 
activating both MAPK and Akt pathways, resulting on 
an overexpression of VEGF and an augmentation of the 
vascularity of the tumor (57). 
Many non-coding RNAs (ncRNAs) have been described 
in NSCLC, being involved in various processes of cancer 
formation and evolution (58,59) (Table 1). Rabinowits et al. 
carried one of the first studies concerning the possibility of 
using exosomes as a source of genetic material derived from 
the tumor comparing the miRNA content between the 
exosomes and the tumoral cells from patients with NSCLC 
and with healthy donors. Although the study revealed no 
differences between both compartments (72) it opened 
a window for tumor molecular identification. In a proof 
of concept, in a small cohort of patients with diagnosed 
NSCLC and a group of healthy donors, Rolfo et al. 
demonstrated the upregulation of two miRNA related with 
the EGFR pathway, 30b and 30c (60).
In a study that included 28 NSCLC patients, 365 
miRNAs were analyzed and the level of let-7f and miR-30e-
3p in were found to be associated with poor outcome. The 
authors also found that patients with more advanced stage 
of disease and lymph node metastases had higher exosome 
related miR-20b levels (62). miRNA-373 and miRNA-512 
Figure 2 Pleiotropic roles of tumor derived exosomes (DEX).
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are tumor suppressor miRNA that are silenced in the tumor 
and whose reactivation produces a restriction of the growth 
and invasiveness of the tumor. Studying exosomes it has been 
demonstrated that the downregulation of these two miRNAs 
is associated with as a poor prognosis in NSCLC patients 
and that therapy that affects epigenetic status led to re-
expression of both miRNAs which, on one side, augmented 
cisplatin-induced apoptosis while, on the other side inhibited 
cell migration (61). Other miRNAs present in the exosomes 
have been identified as possible biomarkers in response to 
certain treatments. miR-29a-3p and miR-150-5p were shown 
to decrease with increasing radiation dose so, and therefore 
identified as a reproducible circulating biomarkers that 
correlated with delivered radiotherapy dose (63). In another 
example, miR-208a and miR-1246 through the binding to 
p21 and DR5 mRNAs respectively, have been reported to 
promote tumor progression and resistance to radiotherapy 
(64,65). Also miR-302b has been described to block the 
cell proliferation and cell migration through interaction 
with its target, the mRNA of TGFβRII (66). Finally, our 
group recently described recently a correlation between the 
overexpression of miR-221-3p and 222-3p, both related with 
EGFR status, and a good clinical outcome in patients under 
osimertinib treatment (67). In addition to miRNAs, other 
ncRNAs have been identified inside the tumor-DEX, such 
as lncRNAs; non-coding RNA molecules with more than 
200 bp with either tumor suppressor or oncogenic functions. 
However, the study of ncRNAs is less extended due to a 
lower general knowledge in the field and the lack of known 
function of many lncRNAs. In this regard, some lncRNAs 
have been described and studied in lung cancer but it has 
not been elucidated if are also present in exosomes. A good 
example of this is HOTAIR a largely studied onco-lncRNA 
related with resistance to cisplatin in NSCLC through p21 
that has been also related with proliferation, migration and 
invasion (70,71). 
Exosomes have been considered also as possible vehicles 
for the selective and directed administration of drugs. In 
lung cancer two clinical trials were planned, a Phase I trial 
in which DEX immunotherapy were used, and a Phase II 
in which DEXs vaccination with exosomes carrying IL-
15Ra and NKG2D in association with cyclophosphamide 
after platinum-based chemotherapy. The main objective 
of both studies was to measure the toxicity and they had 
positive results, concluding that DEXs are able to activate 
the adaptive and the innate immune system (68,73). 
Discussion
Thanks to the lipid bilayer that makes the cargo very stable, 
exosomes allow the analysis of genetic material in order 
to identify the tumor of origin, mutations and possible 
resistances for the treatments, among others. However, 
some methodological issues are still focus of debate and 
Table 1 Principal miRNAs detected in NSCLC, their principal molecule of pathway targeted and its function (if known)
Non-coding RNA Molecule or pathway targeted Clinical relevance References
miRNA
miR-30b; miR-30c EGFR pathway — (60)
miR-373; miR-512 RelA and PIK3CA RNAs; TEAD4 Silenced. Upregulation results in tumor suppressor effects (61)
miR-30e-3p; let-7f — Advanced non-resectable tumors (62)
miR-20b — Metastasis in lymphatic nodes (62)
miR-29a-3p; miR-150-5p — Toxicity in response to radiotherapy (63)
miR-208a p21 Tumor progression. Resistance to radiotherapy (64)
miR-1246 DR5 Tumor progression. Resistance to radiotherapy (65)
miR-302b TGFbRII Downregulated. Tumor suppressor. Blocks cell proliferation 
and migration
(66)
miR-221-3p EGFR Upregulation. Better clinical outcome (67)
miR-222-3p EGFR Upregulation. Better clinical outcome (67)
miR-1228 — Endogenous control (67-69)
lncRNAs
HOTAIR p21 Resistance to cisplatin (70,71)
miRNAs, microRNA; NSCLC, non-small cell lung cancer; lncRNAs, long non-coding RNA; HOTAIR, exosomal non-coding RNA.
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need better implementations. For the moment, there are no 
standardized methods to extract exosomes. The most used 
protocol relies in ultracentrifugation in sucrose gradient, a 
step that is complicated to implement in the clinical setting 
due to the lack of expertise in the field of many laboratories. 
Some companies have started the development of user 
friendly and reproducible kits to improve the time, the 
quality and the yield of exosome extraction.
Some other controversial issues remain in exosome 
research. One of the key factors for exosome production 
and function is the cell or tissue microenvironment. For 
the in vitro analysis, most of the studies are performed in 
completely artificial monolayer of cultured tumor cells. 
To avoid this spatial problem Villasante et al. have recently 
published a technique based in a three dimensional tumor 
model to bypass the effect of culture microenvironment in 
tumor exosomes production (69).
In quantitative studies, another important problem 
is still the absence of endogenous control for exosomal 
miRNA titration. Some groups have described the miR-
1228 as a good endogenous control in several investigations 
(67,74,75), but definitively, more studies are needed to 
validate this finding..
In conclusion, liquid biopsies have become a reality in 
lung cancer. The learning curve for oncologists includes 
CTCs and the current hot topic, circulating free DNA. 
Exosomes are still an area of research but they are likely to 
be implemented in the clinical practice in the near future, 
opening a new window in the cancer prediction, prognosis 
and treatment. Although more efforts are required in order 
standarize exosome isolation and analysis so that they 
can be implemented in the clinical setting, step by step 
we understand more of the exosome-related physiologic 
processes and their impact in carcinogenesis. The main 
point about exosomes is their pleiotropic role in cancer, not 
only as biomarkers but also as a sort of “Pandora box” that 
contains the "instructions" for migration and aggressiveness 
of the tumor and information about druggable targets. We 
are only in the beginning of the long, promising history of 
this new component of the liquid biopsy family. 
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